Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash from Financing Activities (2020 - 2025)

Rapid Micro Biosystems' Cash from Financing Activities history spans 6 years, with the latest figure at $19.2 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 31452.46% year-over-year to $19.2 million; the TTM value through Sep 2025 reached $19.3 million, up 9708.12%, while the annual FY2024 figure was $203000.0, 36.24% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $19.2 million at Rapid Micro Biosystems, up from -$298000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $139.3 million in Q3 2021 and bottomed at -$1.4 million in Q2 2021.
  • The 5-year median for Cash from Financing Activities is $61000.0 (2024), against an average of $12.5 million.
  • The largest annual shift saw Cash from Financing Activities soared 2786080.0% in 2021 before it plummeted 2880.0% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.3 million in 2021, then soared by 106.93% to $87000.0 in 2022, then crashed by 113.79% to -$12000.0 in 2023, then soared by 50.0% to -$6000.0 in 2024, then soared by 320883.33% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Cash from Financing Activities are $19.2 million (Q3 2025), -$298000.0 (Q2 2025), and $379000.0 (Q1 2025).